|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||346.50 - 352.40|
|52-week range||293.05 - 384.20|
|Beta (5Y monthly)||0.28|
|PE ratio (TTM)||21.49|
|Earnings date||03 Feb 2022|
|Forward dividend & yield||9.10 (2.63%)|
|Ex-dividend date||18 Mar 2021|
|1y target est||392.21|
The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.
Roche Holding AG (RHHBY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
SOUTH SAN FRANCISCO, Calif., January 25, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic